sftd
Gleevec®, Proven Safe and Effective Over The Long Term
Filed in archive Cancer , Studies , Treatment by Gloria Gamat on November 13, 2007
According to a study pre-published online in Blood, the official journal of the American Society of Hematology, the drug Gleevec® (imatinib mesylate) proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML).

gleevec_400.jpg



According to Hagop Kantarjian, MD, the lead author on the study and Chairman and Professor of the Leukemia Department at the University of Texas M.D. Anderson Cancer Center:

"The long-term follow-up results of imatinib in CML post interferon failure reassure us of the high efficacy of the drug and its safety.

With a six-year follow-up, the estimated six-year survival rate is 76 percent. In historical data, after interferon failure the average survival was about three to four years."


Gleevec® (imatinib mesylate) - a product of Novartis - when first approved for CML has since been the standard of care for the disease.

Find more details from the American Society of Hematology.

[Photo Credit. www.drugs.com]

Permalink: Gleevec®, Proven Safe and Effective Over The Long Term
Tags: Gleevec  imatinib  chronic  myeloid  leukemia  CML  contact  contact+lenses 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/101967
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Gleevec®, Proven Safe and Effective Over The Long Term:

  • Currently 7.33/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 7.33 out of 6 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!